Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	y VIRTUS HEALTH LIMITED
ABN	80 129 643 492

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Susan Channon
Date of last notice	19 September 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ryletro Pty Ltd is the holder of Performance Rights. Ms Channon is a shareholder and director of the holder of Ryletro Pty Ltd.	
Date of change	09 November 2016	
No. of securities held prior to change	Direct Interests: 354,881 Fully paid ordinary shares 58,825 Performance Rights Indirect Interests: 36,472 Performance Rights	
Class	Performance Rights	
Number acquired	Direct Interests: 38,989 options	
Number disposed	Nil	

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	
No. of securities held after change	Direct Interests: 354,881 Fully paid ordinary shares 97,814 Performance Rights Indirect Interests: 36,472 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of Performance Rights under the Virtus Health Limited Executive Option Plan, approved by shareholders at the Annual General Meeting held on 09 November 2016.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which interest related prior	
to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	
-	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Date of Notice: 14 November 2016

⁺ See chapter 19 for defined terms.